Register for Digital Look

Pharma veteran Simon Jose joining Idorsia as chief commercial officer

By Josh White

Date: Tuesday 23 Oct 2018

Pharma veteran Simon Jose joining Idorsia as chief commercial officer

(Sharecast News) - Idorsia confirmed on Tuesday that Simon Jose would join the company as chief commercial officer on 1 December, and would also be a member of the company's executive committee.
The Swiss pharmaceuticals maker siad Jose is a British national with more than 30 years of experience in the industry, including seven years in the United States.

In that time, he held various commercial roles of "growing responsibility", gaining experience in sales, managing and launching multi-billion dollar products, developing global strategies, and working with research and development to develop competitive pipelines.

Idorsia noted that in 2008, Jose was appointed as general manager of GlaxoSmithKline's home market in the UK.

In 2012, he was appointed president of Stiefel - a global specialty dermatology company recently acquired by GSK.

It said that in that role, Jose led the global executive team, managing an organization of 3,000 people through a period of "significant" change.

From 2015 and immediately prior to Idorsia, he was the senior vice-president, head global franchises and platforms at GSK, where he led combined commercial and medical teams for respiratory, immuno-inflammation, oncology, and infectious diseases.

"I am very pleased and honored that Simon Jose has joined the team at Idorsia," said chief executive officer Jean-Paul Clozel.

"Simon will be key to realising the full potential of our assets and making strategic decisions on how to commercialise them."

Closel said Jose was bringing a "wealth of experience" and "broad expertise" covering the general practitioner market, as well as specialty care.

"He also brings the necessary understanding of the US environment.

"I look forward to working with Simon as he creates and builds our commercial organisation to deliver our innovative therapies to patients."

Simon Jose added that he was attracted to Idorsia by the "quality and breadth" of its pipeline.

"It has great potential across a number of different medical settings, which from a commercial perspective, is incredibly exciting and challenging," Jose explained.

"As I have learned more about Idorsia and the people working there, it is clear that the pipeline is borne from a focus on quality science and a commitment to patients, two attributes which personally drive me.

"I have been struck by the enthusiasm and passion I have experienced at Idorsia and relish the opportunity to build a successful commercial organisation from the ground up."

Idorsia also published its third-quarter results on Tuesday, maintaining its expectations for the full year after sustaining losses in the nine months ended 30 September.


Email this article to a friend

or share it with one of these popular networks:

Top of Page